Chief Medical Officer
Rosh was appointed Chief Medical Officer of Indivior in November 2019.
Rosh is a UK-trained Medical Doctor, with 7 years’ experience in clinical practice, and 20 years senior leadership experience in BioPharma. The majority of his career has been dedicated to the development and commercialization of life saving medicines to improve patient care across multiple therapeutic areas and multiple geographies.
Following a period of clinical practice in the National Health Service in the UK in hospitals across London, Rosh joined the BioPharma industry, where over the past 20 years he has worked in a series of senior leadership roles of increasing responsibility in both large and mid-sized BioPharma companies, including Novartis Oncology, Onyx, and Amgen, across multiple geographies.
While at Novartis, Rosh led medical affairs departments in Global, and led clinical development and medical affairs departments in the US organization and in Australia/New Zealand, with a focus on Oncology, Hematology, and Rare Diseases.
At Onyx, Rosh sat on the Executive Committee and headed up Global Medical and Scientific Affairs for the company.
More recently at Amgen, Rosh led a department of 400 associates covering Global, US, and all ex-regions across all Amgen therapeutic areas.
Rosh holds a Medical Doctor degree from Charing Cross and Westminster Medical School in London, UK, and in addition holds the postgraduate internal medicine degree of MRCP(UK) – Membership of the Royal College of Physicians.